Reducing the dose of gonadotrophin-releasing hormone agonist on starting ovarian stimulation: effect on ovarian response and in-vitro fertilization outcome

By Elgendy M   Afnan M  

Human Reproduction, Vol. 13, Iss. 9, 1998-09 ,pp. : 2382-2385

Oxford University Press

Access to resources Recommend Favorite

Influence of gonadotrophin-releasing hormone agonist total dose in the ovarian stimulation in the long down-regulation protocol for in-vitro fertilization

By Alvarez C.   Cremades N.   Blasco N.   Bernabeu R.  

Human Reproduction, Vol. 12, Iss. 11, 1997-11 ,pp. : 2366-2369

Oxford University Press

Access to resources Recommend Favorite

Case report. First established pregnancy after controlled ovarian hyperstimulation with recombinant follicle stimulating hormone and the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462)

By Itskovitz-Eldor J  

Human Reproduction, Vol. 13, Iss. 2, 1998-02 ,pp. : 294-295

Oxford University Press

Access to resources Recommend Favorite

Endometrial ultrasonography as a predictor of pregnancy in an in-vitro fertilization programme after ovarian stimulation and gonadotrophin-releasing hormone and gonadotrophins

By Oliveira J.B.A.   Baruffi R.L.R.   Mauri A.L.   Petersen C.G.   Borges M.C.   Franco J.G.  

Human Reproduction, Vol. 12, Iss. 11, 1997-11 ,pp. : 2515-2518

Oxford University Press

Access to resources Recommend Favorite

A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon®).

By ganirelix dose-finding study group The  

Human Reproduction, Vol. 13, Iss. 11, 1998-11 ,pp. : 3023-3031

Oxford University Press

Access to resources Recommend Favorite